MX368870B - Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas. - Google Patents

Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.

Info

Publication number
MX368870B
MX368870B MX2016007947A MX2016007947A MX368870B MX 368870 B MX368870 B MX 368870B MX 2016007947 A MX2016007947 A MX 2016007947A MX 2016007947 A MX2016007947 A MX 2016007947A MX 368870 B MX368870 B MX 368870B
Authority
MX
Mexico
Prior art keywords
activity
vortioxetine
treatment
depressive disorder
kappa
Prior art date
Application number
MX2016007947A
Other languages
English (en)
Spanish (es)
Other versions
MX2016007947A (es
Inventor
Sanchez Morillo Connie
N Smagin Gennady
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368870(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2016007947A publication Critical patent/MX2016007947A/es
Publication of MX368870B publication Critical patent/MX368870B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016007947A 2013-12-20 2014-12-18 Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas. MX368870B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16
PCT/EP2014/078515 WO2015091833A1 (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Publications (2)

Publication Number Publication Date
MX2016007947A MX2016007947A (es) 2016-09-09
MX368870B true MX368870B (es) 2019-10-21

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007947A MX368870B (es) 2013-12-20 2014-12-18 Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.

Country Status (14)

Country Link
US (1) US10376506B2 (https=)
EP (1) EP3082815B1 (https=)
JP (1) JP6448645B2 (https=)
KR (1) KR20160093025A (https=)
CN (1) CN105828821B (https=)
AU (1) AU2014368548B2 (https=)
CA (1) CA2933733A1 (https=)
CL (1) CL2016001570A1 (https=)
ES (1) ES2694352T3 (https=)
IL (1) IL246253A0 (https=)
MX (1) MX368870B (https=)
RU (1) RU2679661C1 (https=)
SG (1) SG11201604944PA (https=)
WO (1) WO2015091833A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3876938A4 (en) 2018-11-06 2022-08-10 Purdue Pharma L.P. COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2025197843A1 (ja) * 2024-03-18 2025-09-25 学校法人東京理科大学 アンヘドニアの治療又は予防用医薬組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2003224742A1 (en) 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
DK2001456T3 (da) * 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
US20070259939A1 (en) 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
PL2044043T5 (pl) 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
ES2564006T3 (es) 2009-05-25 2016-03-17 H. Lundbeck A/S Preparación de hidrocloruro de nalmefeno a partir de naltrexona
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
PH12012502153A1 (en) 2010-04-30 2013-02-04 Takeda Pharmaceuticals Co Enteric tablet
SMT201700177T1 (it) 2010-11-05 2017-05-08 H Lundbeck As Procedimento per la fabbricazione di naltrexone
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
CA2909506C (en) 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
CA2909504C (en) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with mood disorder

Also Published As

Publication number Publication date
KR20160093025A (ko) 2016-08-05
WO2015091833A1 (en) 2015-06-25
EP3082815B1 (en) 2018-10-03
AU2014368548A1 (en) 2016-06-30
JP6448645B2 (ja) 2019-01-09
CN105828821B (zh) 2019-04-09
MX2016007947A (es) 2016-09-09
US10376506B2 (en) 2019-08-13
SG11201604944PA (en) 2016-07-28
CN105828821A (zh) 2016-08-03
JP2016540030A (ja) 2016-12-22
CA2933733A1 (en) 2015-06-25
EP3082815A1 (en) 2016-10-26
ES2694352T3 (es) 2018-12-20
IL246253A0 (en) 2016-07-31
AU2014368548B2 (en) 2019-09-19
US20160310488A1 (en) 2016-10-27
RU2016123972A (ru) 2018-01-25
RU2679661C1 (ru) 2019-02-12
CL2016001570A1 (es) 2016-12-09

Similar Documents

Publication Publication Date Title
IL286759A (en) Therapeutic methods and preparations
MX368870B (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
IL246020A0 (en) Compounds and methods for delivery of anti-staphylococcal factors via phagocytes
IL244240B (en) Aminoheteroaryl benzamides as kinase inhibitors
IL242701B (en) Preparations of irna 6tmprss and methods of using them
ZA201505011B (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SG11201507332SA (en) Therapeutic compounds and compositions
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
SG11201601471SA (en) Diagnostic methods and compositions for treatment of glioblastoma
GB201314312D0 (en) Composition and delivery system
SG11201508167PA (en) Therapeutic compositions and uses thereof
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
IN2013MU03641A (https=)
IL241555B (en) Preparations for the treatment of xerostomia and dental care
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
IL244537A0 (en) New administration preparations and methods of their use
HUE040421T2 (hu) Készítmények és eljárások 1-es típusú cukorbetegség kezelésére
IN2013MU02208A (https=)
GB201319255D0 (en) Therapeutic compositions and methods

Legal Events

Date Code Title Description
FG Grant or registration